Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Overweight rating on Sangamo Therapeutics (NASDAQ:SGMO) but lowered the price target from $11 to $9.

August 09, 2023 | 4:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Sangamo Therapeutics but lowered the price target from $11 to $9.
The lowering of the price target by Barclays from $11 to $9 indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that the stock is still expected to outperform. This mixed signal could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100